dr. suresh ramalingam on frontline osimertinib data in egfr nsclc
Published 8 years ago • 318 plays • Length 2:04Download video MP4
Download video MP3
Similar videos
-
2:34
dr. ramalingam on flaura findings in egfr-mutant nsclc
-
9:49
osimertinib as frontline therapy for egfr-positive nsclc
-
1:40
dr. ramalingam on the role of osimertinib in egfr t790m-positive advanced nsclc
-
1:50
researcher comment: positive os data for osimertinib in flaura trial | suresh ramalingam
-
1:19
dr. ramalingam on the significance of the flaura trial in nsclc
-
6:50
osimertinib: a potential new standard of care for advanced egfr-mutated nsclc | suresh ramalingam
-
5:06
front-line osimertinib significantly lengthens overall survival in egfr-mutation positive nsclc
-
1:08
dr. ramalingam on the os results of the flaura trial in egfr-mutant nsclc
-
1:45
dr. ramalingam on the use of osimertinib in clinical trial and real-world settings
-
1:05
dr. ramalingam on the activity of osimertinib combinations in nsclc
-
2:09
dr. ramalingam on flaura trial results in egfr-mutant nsclc
-
0:47
suresh ramalingam, md, on how the flaura trial may impact care for egfr-mutated nsclc
-
0:53
ramalingam compares third generation egfr tki osimertinib to older agents in nsclc
-
0:56
dr. ramalingam on treatment parameters for osimertinib in lung cancer
-
1:21
dr. suresh s. ramalingam on optimizing immunotherapies in lung cancer
-
8:11
advances in frontline therapy for egfr nsclc
-
3:59
osimertinib for egfr t790m resistance mutations in nsclc
-
1:24
suresh ramalingam, md, fasco, shares results from the flaura trial presented at esmo 2019
-
4:04
treating with osimertinib in egfr-mutated nsclc